SlideShare a Scribd company logo
EVALUATION OF DRUG
EFFECTS
RITHIKA. R.S | II M. SC. BIOINFORMATICS,
DEPARTMENT OF BIOINFORMATICS,
SRI KRISHNA ARTS AND SCIENCE COLLEGE, COIMBATORE.
DRUG EFFECT
The drug effect is the quantifiable change in disease processes that result from
the pharmacological or physical properties of an active treatment.
Difference between action and effect of drug:
◦ Actions of drugs are the biochemical physiological mechanisms by which the
chemical produces a response in living organisms.
◦ The effect is the observable consequence of a drug action.
DEPARTMENT OF BIOINFORMATICS, SKASC 2
Why evaluation of drug effects???
 To figure out the effectiveness of the drug
 To check the toxicity of the drug
 If symptoms of a serious side effect is present
DEPARTMENT OF BIOINFORMATICS, SKASC 3
Variations in drug effects…
Patient characteristics
1. Age
2. Gender
3. Ethnicity
4. Genetic Constitution
5. Food style/ Life style
6. Environment
7. Co-existing disorder
Drug factors
1. Type of drug
2. Route of administration
3. Treatment duration
4. Dosage
DEPARTMENT OF BIOINFORMATICS, SKASC 4
Evaluation with existing knowledge
• Unlike beneficial effects adverse effects is vast, ranging from mild symptoms to fatal
events.
• Some adverse effects are predictable from the pharmacological properties and are
easily monitored while others are rather unusual.
• Based on past knowledge of recognized findings of drugs or a strong link with the
mechanism of action of the drug.
• Bradycardia with beta-blockers, and cardiac arrhythmias with amiodarone are very
well monitored in cardiovascular trials.
DEPARTMENT OF BIOINFORMATICS, SKASC 5
Spontaneous reporting
 Distinct clinical features are likely to be captured through spontaneous
reporting, case reports or case series.
 Progressive multifocal leukoencephalopathy is a rare, severe viral infection
associated with certain biologic agents.
 Even non-severe, reversible events may be captured through spontaneous
reporting because of the distinctive features, such as corneal deposits with
amiodarone.
DEPARTMENT OF BIOINFORMATICS, SKASC 6
Follow-up evaluation
 The purpose of the follow-up evaluation is to determine the patient's outcomes
 Both effectiveness and drug safety are evaluated
 Includes measurable improvement in clinical signs and symptoms and/or laboratory
values
 Includes evidence of adverse drug reactions and/or toxicity.
 In, follow-up evaluation is the step in which actual results and outcomes are
documented.
DEPARTMENT OF BIOINFORMATICS, SKASC 7
Randomized Controlled Studies
 Evaluation in which the population receiving treatment is chosen at random from the eligible
population, and a control group is also chosen at random from the same eligible population.
 Myocardial infarction is common and expected in patients with diabetes, controlled clinical
data from RCTs and large pharmaco-epidemiological studies would be the most useful sources.
 Mild events which are typically seen in the general population (e.g. muscle ache with statins,
cough with angiotensin-converting enzyme [ACE] inhibitors) are Likely to be detected in
Randomized Controlled Studies that rely on pharmaco-epidemiological databases of hospital
admissions.
DEPARTMENT OF BIOINFORMATICS, SKASC 8
Time of study
 The timing of the studies are also crucial as the detection and reporting of a
particular adverse event may increase exponentially as the suspicion with a
new signal grows with time.
 For example, the cardiovascular adverse effects of thiazolidinediones, earlier
trials has not have provided any adverse effects data, but after subsequent trials
have yielded much more data.
DEPARTMENT OF BIOINFORMATICS, SKASC 9
Case – Control study
 A study that compares two groups of people: those with the disease or
condition under study (cases) and a very similar group of people who do not
have the disease or condition (controls).
 Case-Control study design is a type of observational study.
DEPARTMENT OF BIOINFORMATICS, SKASC 10
Quantitative analysis
For quantitative analysis of relative risk, we need to consider three key aspects:
1. Typical background incidence of the adverse outcome in unexposed
patients,
2. Onset (timing) of event relative to drug exposure
3. Anticipated magnitude of increase in risk with the drug
DEPARTMENT OF BIOINFORMATICS, SKASC 11
Meta analysis
 Meta-analysis is a quantitative, formal, epidemiological study design used to
systematically assess the results of previous research to derive conclusions about that
body of research.
 Typically, the study is based on randomized, controlled clinical trials.
 A method for systematically combining qualitative study data from several selected studies to
develop a single conclusion that has greater statistical power.
 This conclusion is statistically stronger than the analysis of any single study, due to increased
numbers of subjects.
DEPARTMENT OF BIOINFORMATICS, SKASC 12
Data sources
Source Example
Product Information sheets UK ABPI electronic Medicines Compendium (eMC)
Regulatory authorities bulletins
and drug reviews
• Canadian Adverse Reaction Newsletter (CARN)
• Drug Safety Update (UK)
• FDA Medwatch
• Australian Medicines Safety
• Netherlands LAREB updates
• FDA Drug Approval
Pharmaceutical company study
registers
• Clinical Study Results Database,(http://www.clinicalstudyresults.org/ )
• International Federation of Pharmaceutical Manufacturers and Associations
(IFPMA) clinical trials portal, (clinicaltrials.ifpma.org/ )
• Lead Discovery (http://www.leaddiscovery.co.uk )
• GlaxoSmithKline clinical study register, (http://www.gsk-
clinicalstudyregister.com )
DEPARTMENT OF BIOINFORMATICS, SKASC 13
Source Example
Spontaneous reporting • Adverse Drug Reactions Database
• Canada’s Adverse Drug Reaction Database,
• UK Yellow Card scheme: Drug Analysis Prints (DAPs), Netherlands LAREB,
http://www.lareb.nl/kennis/zoeksignalen.asp
• DIOGENES: Adverse Drug Events Database for data from the Food and Drug
Administration (FDA) US MedWatch service,
• PharmaPendium, FDA's Adverse Event Reporting System (AERS) and
Spontaneous Reporting System (SRS),
• Vigibase Services: Uppsala Monitoring Centre (WHO) collects individual
reports from 77 countries
Bibliographic databases TOXLINE (Toxicology Literature Online), MEDLINE, EMBASE, BIOSIS,
Derwent Drug File, International Pharmaceutical Abstracts (IPA), Iowa Drug
Information Service (IDIS), PASCAL, Science Citation Index (SCI)
DEPARTMENT OF BIOINFORMATICS, SKASC 14
Data sources
References
1. Coleman JJ, Pontefract SK. Adverse drug reactions. Clin Med (Lond). 2016 Oct;16(5):481-
485. doi: 10.7861/clinmedicine.16-5-481. PMID: 27697815; PMCID: PMC6297296.
2. Loke YK, Golder SP, Vandenbroucke JP. Comprehensive evaluations of the adverse effects of
drugs: importance of appropriate study selection and data sources. Ther Adv Drug Saf. 2011
Apr;2(2):59-68. doi: 10.1177/2042098611401129. PMID: 25083202; PMCID: PMC4110807.
3. https://www.msdmanuals.com/en-in/professional/clinical-pharmacology/adverse-drug-
reactions/adverse-drug-reactions
4. https://accesspharmacy.mhmedical.com/content.aspx?bookid=491&sectionid=39674908
DEPARTMENT OF BIOINFORMATICS, SKASC 15
DEPARTMENT OF BIOINFORMATICS, SKASC 16
THANK YOU

More Related Content

Similar to EVALUATION OF DRUG EFFECTS.pdf

Ch 2 basic concepts in pharmacoepidemiology (10 hrs)
Ch 2 basic concepts in pharmacoepidemiology (10 hrs)Ch 2 basic concepts in pharmacoepidemiology (10 hrs)
Ch 2 basic concepts in pharmacoepidemiology (10 hrs)University of Gondar
 
David Neasham Practical Use Pharmacoepi Drug Dev
David Neasham Practical Use Pharmacoepi Drug DevDavid Neasham Practical Use Pharmacoepi Drug Dev
David Neasham Practical Use Pharmacoepi Drug Devguest41e570
 
David Neasham Practical Use Pharmacoepi Drug Dev
David Neasham Practical Use Pharmacoepi Drug DevDavid Neasham Practical Use Pharmacoepi Drug Dev
David Neasham Practical Use Pharmacoepi Drug Devguest41e570
 
How to recognize ADRs in patients.@ Clinical Pharmacy
How to recognize ADRs in patients.@ Clinical PharmacyHow to recognize ADRs in patients.@ Clinical Pharmacy
How to recognize ADRs in patients.@ Clinical PharmacyDrpradeepthi
 
Vareniclina e riscos cardiovasculares
Vareniclina e riscos cardiovascularesVareniclina e riscos cardiovasculares
Vareniclina e riscos cardiovascularesFlávia Salame
 
importance of pharmcovigilance
importance of pharmcovigilanceimportance of pharmcovigilance
importance of pharmcovigilancesiddemsetty nikhil
 
statistical analysis by apurva.pdf
statistical analysis by apurva.pdfstatistical analysis by apurva.pdf
statistical analysis by apurva.pdfApurva Pawar
 
Pharmacovigilance by bishnu koirala
Pharmacovigilance by bishnu koiralaPharmacovigilance by bishnu koirala
Pharmacovigilance by bishnu koiralaBishnu Koirala
 
2015 04-13 Pharma Nutrition 2015 Philadelphia Alain van Gool
2015 04-13 Pharma Nutrition 2015 Philadelphia Alain van Gool2015 04-13 Pharma Nutrition 2015 Philadelphia Alain van Gool
2015 04-13 Pharma Nutrition 2015 Philadelphia Alain van GoolAlain van Gool
 
Pharmacovigilance overview
Pharmacovigilance overviewPharmacovigilance overview
Pharmacovigilance overviewAcri India
 
Pharmacoepidemiology 110727114004-phpapp01
Pharmacoepidemiology 110727114004-phpapp01Pharmacoepidemiology 110727114004-phpapp01
Pharmacoepidemiology 110727114004-phpapp01Khadga Raj
 
20091109 Biol1010 Personalized Medicine
20091109 Biol1010 Personalized Medicine20091109 Biol1010 Personalized Medicine
20091109 Biol1010 Personalized MedicineMichel Dumontier
 
Phase IV clinical trial.pptx
Phase IV clinical trial.pptxPhase IV clinical trial.pptx
Phase IV clinical trial.pptxDr Abisha T
 
Randomized clinical trials
Randomized clinical trialsRandomized clinical trials
Randomized clinical trialsAhmed Nouri
 
Drug Information Association Clinical Forum Presentation
Drug Information Association Clinical Forum PresentationDrug Information Association Clinical Forum Presentation
Drug Information Association Clinical Forum Presentationdneasha
 
Drug Information Association Clinical Forum Presentation
Drug Information Association Clinical Forum PresentationDrug Information Association Clinical Forum Presentation
Drug Information Association Clinical Forum Presentationdneasha
 
Overuse of Stress Ulcer prophylaxis (SUP)
Overuse of Stress Ulcer prophylaxis (SUP)Overuse of Stress Ulcer prophylaxis (SUP)
Overuse of Stress Ulcer prophylaxis (SUP)Neveen Karima
 
Pharmacovigilance & Adverse drug reaction
Pharmacovigilance & Adverse drug reactionPharmacovigilance & Adverse drug reaction
Pharmacovigilance & Adverse drug reactionRahul Bhati
 
Drug Devel Ment
Drug Devel MentDrug Devel Ment
Drug Devel MentMed Bee
 

Similar to EVALUATION OF DRUG EFFECTS.pdf (20)

Ch 2 basic concepts in pharmacoepidemiology (10 hrs)
Ch 2 basic concepts in pharmacoepidemiology (10 hrs)Ch 2 basic concepts in pharmacoepidemiology (10 hrs)
Ch 2 basic concepts in pharmacoepidemiology (10 hrs)
 
David Neasham Practical Use Pharmacoepi Drug Dev
David Neasham Practical Use Pharmacoepi Drug DevDavid Neasham Practical Use Pharmacoepi Drug Dev
David Neasham Practical Use Pharmacoepi Drug Dev
 
David Neasham Practical Use Pharmacoepi Drug Dev
David Neasham Practical Use Pharmacoepi Drug DevDavid Neasham Practical Use Pharmacoepi Drug Dev
David Neasham Practical Use Pharmacoepi Drug Dev
 
How to recognize ADRs in patients.@ Clinical Pharmacy
How to recognize ADRs in patients.@ Clinical PharmacyHow to recognize ADRs in patients.@ Clinical Pharmacy
How to recognize ADRs in patients.@ Clinical Pharmacy
 
Vareniclina e riscos cardiovasculares
Vareniclina e riscos cardiovascularesVareniclina e riscos cardiovasculares
Vareniclina e riscos cardiovasculares
 
importance of pharmcovigilance
importance of pharmcovigilanceimportance of pharmcovigilance
importance of pharmcovigilance
 
statistical analysis by apurva.pdf
statistical analysis by apurva.pdfstatistical analysis by apurva.pdf
statistical analysis by apurva.pdf
 
Pharmacovigilance by bishnu koirala
Pharmacovigilance by bishnu koiralaPharmacovigilance by bishnu koirala
Pharmacovigilance by bishnu koirala
 
2015 04-13 Pharma Nutrition 2015 Philadelphia Alain van Gool
2015 04-13 Pharma Nutrition 2015 Philadelphia Alain van Gool2015 04-13 Pharma Nutrition 2015 Philadelphia Alain van Gool
2015 04-13 Pharma Nutrition 2015 Philadelphia Alain van Gool
 
Pharmacovigilance overview
Pharmacovigilance overviewPharmacovigilance overview
Pharmacovigilance overview
 
Pharmacoepidemiology 110727114004-phpapp01
Pharmacoepidemiology 110727114004-phpapp01Pharmacoepidemiology 110727114004-phpapp01
Pharmacoepidemiology 110727114004-phpapp01
 
20091109 Biol1010 Personalized Medicine
20091109 Biol1010 Personalized Medicine20091109 Biol1010 Personalized Medicine
20091109 Biol1010 Personalized Medicine
 
Phase IV clinical trial.pptx
Phase IV clinical trial.pptxPhase IV clinical trial.pptx
Phase IV clinical trial.pptx
 
Randomized clinical trials
Randomized clinical trialsRandomized clinical trials
Randomized clinical trials
 
My ppt.
My ppt.My ppt.
My ppt.
 
Drug Information Association Clinical Forum Presentation
Drug Information Association Clinical Forum PresentationDrug Information Association Clinical Forum Presentation
Drug Information Association Clinical Forum Presentation
 
Drug Information Association Clinical Forum Presentation
Drug Information Association Clinical Forum PresentationDrug Information Association Clinical Forum Presentation
Drug Information Association Clinical Forum Presentation
 
Overuse of Stress Ulcer prophylaxis (SUP)
Overuse of Stress Ulcer prophylaxis (SUP)Overuse of Stress Ulcer prophylaxis (SUP)
Overuse of Stress Ulcer prophylaxis (SUP)
 
Pharmacovigilance & Adverse drug reaction
Pharmacovigilance & Adverse drug reactionPharmacovigilance & Adverse drug reaction
Pharmacovigilance & Adverse drug reaction
 
Drug Devel Ment
Drug Devel MentDrug Devel Ment
Drug Devel Ment
 

More from RITHIKA R S

Current-good-manufacturing-practices.pdf
Current-good-manufacturing-practices.pdfCurrent-good-manufacturing-practices.pdf
Current-good-manufacturing-practices.pdfRITHIKA R S
 
Protozoal & ricketsia vaccines.pdf
Protozoal & ricketsia vaccines.pdfProtozoal & ricketsia vaccines.pdf
Protozoal & ricketsia vaccines.pdfRITHIKA R S
 
Down syndrome.pdf
Down syndrome.pdfDown syndrome.pdf
Down syndrome.pdfRITHIKA R S
 
FUNCTIONS IN C PROGRAMMING.pdf
FUNCTIONS IN C PROGRAMMING.pdfFUNCTIONS IN C PROGRAMMING.pdf
FUNCTIONS IN C PROGRAMMING.pdfRITHIKA R S
 
DNAfingerprinting poster.pdf
DNAfingerprinting poster.pdfDNAfingerprinting poster.pdf
DNAfingerprinting poster.pdfRITHIKA R S
 
Conditional-probability-and-Bioinformatics.pptx
Conditional-probability-and-Bioinformatics.pptxConditional-probability-and-Bioinformatics.pptx
Conditional-probability-and-Bioinformatics.pptxRITHIKA R S
 
THIRD GEN SEQUENCING.pptx
THIRD GEN SEQUENCING.pptxTHIRD GEN SEQUENCING.pptx
THIRD GEN SEQUENCING.pptxRITHIKA R S
 
CRISPR_cas9_tech.pptx
CRISPR_cas9_tech.pptxCRISPR_cas9_tech.pptx
CRISPR_cas9_tech.pptxRITHIKA R S
 

More from RITHIKA R S (9)

Current-good-manufacturing-practices.pdf
Current-good-manufacturing-practices.pdfCurrent-good-manufacturing-practices.pdf
Current-good-manufacturing-practices.pdf
 
Protozoal & ricketsia vaccines.pdf
Protozoal & ricketsia vaccines.pdfProtozoal & ricketsia vaccines.pdf
Protozoal & ricketsia vaccines.pdf
 
Down syndrome.pdf
Down syndrome.pdfDown syndrome.pdf
Down syndrome.pdf
 
FUNCTIONS IN C PROGRAMMING.pdf
FUNCTIONS IN C PROGRAMMING.pdfFUNCTIONS IN C PROGRAMMING.pdf
FUNCTIONS IN C PROGRAMMING.pdf
 
DNAfingerprinting poster.pdf
DNAfingerprinting poster.pdfDNAfingerprinting poster.pdf
DNAfingerprinting poster.pdf
 
Conditional-probability-and-Bioinformatics.pptx
Conditional-probability-and-Bioinformatics.pptxConditional-probability-and-Bioinformatics.pptx
Conditional-probability-and-Bioinformatics.pptx
 
THIRD GEN SEQUENCING.pptx
THIRD GEN SEQUENCING.pptxTHIRD GEN SEQUENCING.pptx
THIRD GEN SEQUENCING.pptx
 
LAC OPERON.pdf
LAC OPERON.pdfLAC OPERON.pdf
LAC OPERON.pdf
 
CRISPR_cas9_tech.pptx
CRISPR_cas9_tech.pptxCRISPR_cas9_tech.pptx
CRISPR_cas9_tech.pptx
 

Recently uploaded

Plasmapheresis - Dr. E. Muralinath - Kalyan . C.pptx
Plasmapheresis - Dr. E. Muralinath - Kalyan . C.pptxPlasmapheresis - Dr. E. Muralinath - Kalyan . C.pptx
Plasmapheresis - Dr. E. Muralinath - Kalyan . C.pptxmuralinath2
 
Tissue engineering......................pptx
Tissue engineering......................pptxTissue engineering......................pptx
Tissue engineering......................pptxCherry
 
Hemoglobin metabolism: C Kalyan & E. Muralinath
Hemoglobin metabolism: C Kalyan & E. MuralinathHemoglobin metabolism: C Kalyan & E. Muralinath
Hemoglobin metabolism: C Kalyan & E. Muralinathmuralinath2
 
Microbial bio Synthesis of nanoparticles.pptx
Microbial bio Synthesis of nanoparticles.pptxMicrobial bio Synthesis of nanoparticles.pptx
Microbial bio Synthesis of nanoparticles.pptxCherry
 
electrochemical gas sensors and their uses.pptx
electrochemical gas sensors and their uses.pptxelectrochemical gas sensors and their uses.pptx
electrochemical gas sensors and their uses.pptxHusna Zaheer
 
ERTHROPOIESIS: Dr. E. Muralinath & R. Gnana Lahari
ERTHROPOIESIS: Dr. E. Muralinath & R. Gnana LahariERTHROPOIESIS: Dr. E. Muralinath & R. Gnana Lahari
ERTHROPOIESIS: Dr. E. Muralinath & R. Gnana Laharimuralinath2
 
Climate extremes likely to drive land mammal extinction during next supercont...
Climate extremes likely to drive land mammal extinction during next supercont...Climate extremes likely to drive land mammal extinction during next supercont...
Climate extremes likely to drive land mammal extinction during next supercont...Sérgio Sacani
 
Ostiguy & Panizza & Moffitt (eds.) - Populism in Global Perspective. A Perfor...
Ostiguy & Panizza & Moffitt (eds.) - Populism in Global Perspective. A Perfor...Ostiguy & Panizza & Moffitt (eds.) - Populism in Global Perspective. A Perfor...
Ostiguy & Panizza & Moffitt (eds.) - Populism in Global Perspective. A Perfor...frank0071
 
INSIGHT Partner Profile: Tampere University
INSIGHT Partner Profile: Tampere UniversityINSIGHT Partner Profile: Tampere University
INSIGHT Partner Profile: Tampere UniversitySteffi Friedrichs
 
A Giant Impact Origin for the First Subduction on Earth
A Giant Impact Origin for the First Subduction on EarthA Giant Impact Origin for the First Subduction on Earth
A Giant Impact Origin for the First Subduction on EarthSérgio Sacani
 
Unveiling The Crucial Role Of Cobalt In Plant
Unveiling The Crucial Role Of Cobalt In PlantUnveiling The Crucial Role Of Cobalt In Plant
Unveiling The Crucial Role Of Cobalt In PlantHimanshu Pandey
 
GBSN - Biochemistry (Unit 4) Chemistry of Carbohydrates
GBSN - Biochemistry (Unit 4) Chemistry of CarbohydratesGBSN - Biochemistry (Unit 4) Chemistry of Carbohydrates
GBSN - Biochemistry (Unit 4) Chemistry of CarbohydratesAreesha Ahmad
 
Plasma proteins_ Dr.Muralinath_Dr.c. kalyan
Plasma proteins_ Dr.Muralinath_Dr.c. kalyanPlasma proteins_ Dr.Muralinath_Dr.c. kalyan
Plasma proteins_ Dr.Muralinath_Dr.c. kalyanmuralinath2
 
Mitosis...............................pptx
Mitosis...............................pptxMitosis...............................pptx
Mitosis...............................pptxCherry
 
Jet reorientation in central galaxies of clusters and groups: insights from V...
Jet reorientation in central galaxies of clusters and groups: insights from V...Jet reorientation in central galaxies of clusters and groups: insights from V...
Jet reorientation in central galaxies of clusters and groups: insights from V...Sérgio Sacani
 
mixotrophy in cyanobacteria: a dual nutritional strategy
mixotrophy in cyanobacteria: a dual nutritional strategymixotrophy in cyanobacteria: a dual nutritional strategy
mixotrophy in cyanobacteria: a dual nutritional strategyMansiBishnoi1
 
Emergent ribozyme behaviors in oxychlorine brines indicate a unique niche for...
Emergent ribozyme behaviors in oxychlorine brines indicate a unique niche for...Emergent ribozyme behaviors in oxychlorine brines indicate a unique niche for...
Emergent ribozyme behaviors in oxychlorine brines indicate a unique niche for...Sérgio Sacani
 
Multi-source connectivity as the driver of solar wind variability in the heli...
Multi-source connectivity as the driver of solar wind variability in the heli...Multi-source connectivity as the driver of solar wind variability in the heli...
Multi-source connectivity as the driver of solar wind variability in the heli...Sérgio Sacani
 
Extensive Pollution of Uranus and Neptune’s Atmospheres by Upsweep of Icy Mat...
Extensive Pollution of Uranus and Neptune’s Atmospheres by Upsweep of Icy Mat...Extensive Pollution of Uranus and Neptune’s Atmospheres by Upsweep of Icy Mat...
Extensive Pollution of Uranus and Neptune’s Atmospheres by Upsweep of Icy Mat...Sérgio Sacani
 
In vitro androgenesis ...............pptx
In vitro androgenesis ...............pptxIn vitro androgenesis ...............pptx
In vitro androgenesis ...............pptxCherry
 

Recently uploaded (20)

Plasmapheresis - Dr. E. Muralinath - Kalyan . C.pptx
Plasmapheresis - Dr. E. Muralinath - Kalyan . C.pptxPlasmapheresis - Dr. E. Muralinath - Kalyan . C.pptx
Plasmapheresis - Dr. E. Muralinath - Kalyan . C.pptx
 
Tissue engineering......................pptx
Tissue engineering......................pptxTissue engineering......................pptx
Tissue engineering......................pptx
 
Hemoglobin metabolism: C Kalyan & E. Muralinath
Hemoglobin metabolism: C Kalyan & E. MuralinathHemoglobin metabolism: C Kalyan & E. Muralinath
Hemoglobin metabolism: C Kalyan & E. Muralinath
 
Microbial bio Synthesis of nanoparticles.pptx
Microbial bio Synthesis of nanoparticles.pptxMicrobial bio Synthesis of nanoparticles.pptx
Microbial bio Synthesis of nanoparticles.pptx
 
electrochemical gas sensors and their uses.pptx
electrochemical gas sensors and their uses.pptxelectrochemical gas sensors and their uses.pptx
electrochemical gas sensors and their uses.pptx
 
ERTHROPOIESIS: Dr. E. Muralinath & R. Gnana Lahari
ERTHROPOIESIS: Dr. E. Muralinath & R. Gnana LahariERTHROPOIESIS: Dr. E. Muralinath & R. Gnana Lahari
ERTHROPOIESIS: Dr. E. Muralinath & R. Gnana Lahari
 
Climate extremes likely to drive land mammal extinction during next supercont...
Climate extremes likely to drive land mammal extinction during next supercont...Climate extremes likely to drive land mammal extinction during next supercont...
Climate extremes likely to drive land mammal extinction during next supercont...
 
Ostiguy & Panizza & Moffitt (eds.) - Populism in Global Perspective. A Perfor...
Ostiguy & Panizza & Moffitt (eds.) - Populism in Global Perspective. A Perfor...Ostiguy & Panizza & Moffitt (eds.) - Populism in Global Perspective. A Perfor...
Ostiguy & Panizza & Moffitt (eds.) - Populism in Global Perspective. A Perfor...
 
INSIGHT Partner Profile: Tampere University
INSIGHT Partner Profile: Tampere UniversityINSIGHT Partner Profile: Tampere University
INSIGHT Partner Profile: Tampere University
 
A Giant Impact Origin for the First Subduction on Earth
A Giant Impact Origin for the First Subduction on EarthA Giant Impact Origin for the First Subduction on Earth
A Giant Impact Origin for the First Subduction on Earth
 
Unveiling The Crucial Role Of Cobalt In Plant
Unveiling The Crucial Role Of Cobalt In PlantUnveiling The Crucial Role Of Cobalt In Plant
Unveiling The Crucial Role Of Cobalt In Plant
 
GBSN - Biochemistry (Unit 4) Chemistry of Carbohydrates
GBSN - Biochemistry (Unit 4) Chemistry of CarbohydratesGBSN - Biochemistry (Unit 4) Chemistry of Carbohydrates
GBSN - Biochemistry (Unit 4) Chemistry of Carbohydrates
 
Plasma proteins_ Dr.Muralinath_Dr.c. kalyan
Plasma proteins_ Dr.Muralinath_Dr.c. kalyanPlasma proteins_ Dr.Muralinath_Dr.c. kalyan
Plasma proteins_ Dr.Muralinath_Dr.c. kalyan
 
Mitosis...............................pptx
Mitosis...............................pptxMitosis...............................pptx
Mitosis...............................pptx
 
Jet reorientation in central galaxies of clusters and groups: insights from V...
Jet reorientation in central galaxies of clusters and groups: insights from V...Jet reorientation in central galaxies of clusters and groups: insights from V...
Jet reorientation in central galaxies of clusters and groups: insights from V...
 
mixotrophy in cyanobacteria: a dual nutritional strategy
mixotrophy in cyanobacteria: a dual nutritional strategymixotrophy in cyanobacteria: a dual nutritional strategy
mixotrophy in cyanobacteria: a dual nutritional strategy
 
Emergent ribozyme behaviors in oxychlorine brines indicate a unique niche for...
Emergent ribozyme behaviors in oxychlorine brines indicate a unique niche for...Emergent ribozyme behaviors in oxychlorine brines indicate a unique niche for...
Emergent ribozyme behaviors in oxychlorine brines indicate a unique niche for...
 
Multi-source connectivity as the driver of solar wind variability in the heli...
Multi-source connectivity as the driver of solar wind variability in the heli...Multi-source connectivity as the driver of solar wind variability in the heli...
Multi-source connectivity as the driver of solar wind variability in the heli...
 
Extensive Pollution of Uranus and Neptune’s Atmospheres by Upsweep of Icy Mat...
Extensive Pollution of Uranus and Neptune’s Atmospheres by Upsweep of Icy Mat...Extensive Pollution of Uranus and Neptune’s Atmospheres by Upsweep of Icy Mat...
Extensive Pollution of Uranus and Neptune’s Atmospheres by Upsweep of Icy Mat...
 
In vitro androgenesis ...............pptx
In vitro androgenesis ...............pptxIn vitro androgenesis ...............pptx
In vitro androgenesis ...............pptx
 

EVALUATION OF DRUG EFFECTS.pdf

  • 1. EVALUATION OF DRUG EFFECTS RITHIKA. R.S | II M. SC. BIOINFORMATICS, DEPARTMENT OF BIOINFORMATICS, SRI KRISHNA ARTS AND SCIENCE COLLEGE, COIMBATORE.
  • 2. DRUG EFFECT The drug effect is the quantifiable change in disease processes that result from the pharmacological or physical properties of an active treatment. Difference between action and effect of drug: ◦ Actions of drugs are the biochemical physiological mechanisms by which the chemical produces a response in living organisms. ◦ The effect is the observable consequence of a drug action. DEPARTMENT OF BIOINFORMATICS, SKASC 2
  • 3. Why evaluation of drug effects???  To figure out the effectiveness of the drug  To check the toxicity of the drug  If symptoms of a serious side effect is present DEPARTMENT OF BIOINFORMATICS, SKASC 3
  • 4. Variations in drug effects… Patient characteristics 1. Age 2. Gender 3. Ethnicity 4. Genetic Constitution 5. Food style/ Life style 6. Environment 7. Co-existing disorder Drug factors 1. Type of drug 2. Route of administration 3. Treatment duration 4. Dosage DEPARTMENT OF BIOINFORMATICS, SKASC 4
  • 5. Evaluation with existing knowledge • Unlike beneficial effects adverse effects is vast, ranging from mild symptoms to fatal events. • Some adverse effects are predictable from the pharmacological properties and are easily monitored while others are rather unusual. • Based on past knowledge of recognized findings of drugs or a strong link with the mechanism of action of the drug. • Bradycardia with beta-blockers, and cardiac arrhythmias with amiodarone are very well monitored in cardiovascular trials. DEPARTMENT OF BIOINFORMATICS, SKASC 5
  • 6. Spontaneous reporting  Distinct clinical features are likely to be captured through spontaneous reporting, case reports or case series.  Progressive multifocal leukoencephalopathy is a rare, severe viral infection associated with certain biologic agents.  Even non-severe, reversible events may be captured through spontaneous reporting because of the distinctive features, such as corneal deposits with amiodarone. DEPARTMENT OF BIOINFORMATICS, SKASC 6
  • 7. Follow-up evaluation  The purpose of the follow-up evaluation is to determine the patient's outcomes  Both effectiveness and drug safety are evaluated  Includes measurable improvement in clinical signs and symptoms and/or laboratory values  Includes evidence of adverse drug reactions and/or toxicity.  In, follow-up evaluation is the step in which actual results and outcomes are documented. DEPARTMENT OF BIOINFORMATICS, SKASC 7
  • 8. Randomized Controlled Studies  Evaluation in which the population receiving treatment is chosen at random from the eligible population, and a control group is also chosen at random from the same eligible population.  Myocardial infarction is common and expected in patients with diabetes, controlled clinical data from RCTs and large pharmaco-epidemiological studies would be the most useful sources.  Mild events which are typically seen in the general population (e.g. muscle ache with statins, cough with angiotensin-converting enzyme [ACE] inhibitors) are Likely to be detected in Randomized Controlled Studies that rely on pharmaco-epidemiological databases of hospital admissions. DEPARTMENT OF BIOINFORMATICS, SKASC 8
  • 9. Time of study  The timing of the studies are also crucial as the detection and reporting of a particular adverse event may increase exponentially as the suspicion with a new signal grows with time.  For example, the cardiovascular adverse effects of thiazolidinediones, earlier trials has not have provided any adverse effects data, but after subsequent trials have yielded much more data. DEPARTMENT OF BIOINFORMATICS, SKASC 9
  • 10. Case – Control study  A study that compares two groups of people: those with the disease or condition under study (cases) and a very similar group of people who do not have the disease or condition (controls).  Case-Control study design is a type of observational study. DEPARTMENT OF BIOINFORMATICS, SKASC 10
  • 11. Quantitative analysis For quantitative analysis of relative risk, we need to consider three key aspects: 1. Typical background incidence of the adverse outcome in unexposed patients, 2. Onset (timing) of event relative to drug exposure 3. Anticipated magnitude of increase in risk with the drug DEPARTMENT OF BIOINFORMATICS, SKASC 11
  • 12. Meta analysis  Meta-analysis is a quantitative, formal, epidemiological study design used to systematically assess the results of previous research to derive conclusions about that body of research.  Typically, the study is based on randomized, controlled clinical trials.  A method for systematically combining qualitative study data from several selected studies to develop a single conclusion that has greater statistical power.  This conclusion is statistically stronger than the analysis of any single study, due to increased numbers of subjects. DEPARTMENT OF BIOINFORMATICS, SKASC 12
  • 13. Data sources Source Example Product Information sheets UK ABPI electronic Medicines Compendium (eMC) Regulatory authorities bulletins and drug reviews • Canadian Adverse Reaction Newsletter (CARN) • Drug Safety Update (UK) • FDA Medwatch • Australian Medicines Safety • Netherlands LAREB updates • FDA Drug Approval Pharmaceutical company study registers • Clinical Study Results Database,(http://www.clinicalstudyresults.org/ ) • International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) clinical trials portal, (clinicaltrials.ifpma.org/ ) • Lead Discovery (http://www.leaddiscovery.co.uk ) • GlaxoSmithKline clinical study register, (http://www.gsk- clinicalstudyregister.com ) DEPARTMENT OF BIOINFORMATICS, SKASC 13
  • 14. Source Example Spontaneous reporting • Adverse Drug Reactions Database • Canada’s Adverse Drug Reaction Database, • UK Yellow Card scheme: Drug Analysis Prints (DAPs), Netherlands LAREB, http://www.lareb.nl/kennis/zoeksignalen.asp • DIOGENES: Adverse Drug Events Database for data from the Food and Drug Administration (FDA) US MedWatch service, • PharmaPendium, FDA's Adverse Event Reporting System (AERS) and Spontaneous Reporting System (SRS), • Vigibase Services: Uppsala Monitoring Centre (WHO) collects individual reports from 77 countries Bibliographic databases TOXLINE (Toxicology Literature Online), MEDLINE, EMBASE, BIOSIS, Derwent Drug File, International Pharmaceutical Abstracts (IPA), Iowa Drug Information Service (IDIS), PASCAL, Science Citation Index (SCI) DEPARTMENT OF BIOINFORMATICS, SKASC 14 Data sources
  • 15. References 1. Coleman JJ, Pontefract SK. Adverse drug reactions. Clin Med (Lond). 2016 Oct;16(5):481- 485. doi: 10.7861/clinmedicine.16-5-481. PMID: 27697815; PMCID: PMC6297296. 2. Loke YK, Golder SP, Vandenbroucke JP. Comprehensive evaluations of the adverse effects of drugs: importance of appropriate study selection and data sources. Ther Adv Drug Saf. 2011 Apr;2(2):59-68. doi: 10.1177/2042098611401129. PMID: 25083202; PMCID: PMC4110807. 3. https://www.msdmanuals.com/en-in/professional/clinical-pharmacology/adverse-drug- reactions/adverse-drug-reactions 4. https://accesspharmacy.mhmedical.com/content.aspx?bookid=491&sectionid=39674908 DEPARTMENT OF BIOINFORMATICS, SKASC 15
  • 16. DEPARTMENT OF BIOINFORMATICS, SKASC 16 THANK YOU